Metastatic collecting duct carcinoma of the kidney treated with sunitinib
© Tazi et al; licensee BioMed Central Ltd. 2011
Received: 4 January 2011
Accepted: 13 July 2011
Published: 13 July 2011
This article has been retracted. The retraction notice can be found here: http://wjso.biomedcentral.com/articles/10.1186/1477-7819-9-136
The Retraction Note to this article has been published in World Journal of Surgical Oncology 2011 9:136
Collecting duct carcinoma (CDC) of the kidney is a rare and aggressive malignant tumor arising from the distal collecting tubules which has been shown to have a poor response to several kinds of systemic therapy. We present a case of metastatic CDC that responded favorably to a multiple tyrosine kinase inhibitor, sunitinib, achieving a partial response in both lung and skeletal metastases. To our knowledge, this is the first report showing therapeutic activity of sunitinib against CDC. Considering these findings, it would be worthwhile prospectively investigating the role of multiple tyrosine kinase inhibitors, particularly sunitinib, in the management of metastatic CDC.
KeywordsCollecting duct carcinoma Sunitinib Metastasis
Collecting duct carcinoma (CDC) of the kidney, also known as Bellini duct carcinoma, is a rare variant of renal cell carcinoma (RCC) arising from the epithelium of the distal collecting ducts; it accounts for 2% of all RCCs . Clinically, CDC is characterized by an extremely aggressive phenotype, accompanying metastatic diseases at presentation in most reported cases; the prognosis ofCDC is therefore poor, with approximately 70% of patients dying of disease progression within 2 years after diagnosis. In fact, several systemic therapies, including cytokine therapy and cytotoxic chemotherapy, have failed to achieve favorable response to metastatic CDC except for very limited cases [2–7]. Sunitinib is an orally available inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and others, with direct antitumor and antiangiogenic activity. Based on impressive outcomes in several clinical trials, sunitinib has been approved worldwide for treatment of RCC patients with clear cell histology . Furthermore, significant therapeutic activities of sunitinib against non-clear cell RCCs, for example papillary and chromophobe carcinomas, have also been reported in recent studies [8, 9]; however, it remains unknown whether sunitinib has a therapeutic impact on CDC of the kidney. Here, we report the first case of a patient with metastatic CDC of the kidney who had a favorable response to sunitinib treatment.
A 47-year-old man with a 14.1 cm left renal mass extending into the renal vein and metastases involving the bilateral lungs and retroperitoneal lymph nodes were referred to our institution.
Because CDC is an uncommon and aggressive disease with extremely poor prognosis, accumulated information about CDC is very limited. Therefore, no established therapy for CDC exists except for surgical resection of localized diseases. To date, however, there have been 14 reported cases of metastatic CDC showing response to systemic therapy, consisting 9, 2, 1, and 1 who were treated by gemcitabine plus cisplatin or carboplatin, paclitaxel plus carboplatin, gemcitabine plus doxorubicin, and interferon-a, respectively [2–7]. Considering these findings in addition to the characteristics of CDC similar to those of urothelial cancer, chemotherapy is the currently favored approach for patients with metastatic CDC.
In the case presented, because of her poor performance status associated with skeletal metastases, it was judged to be difficult to perform intensive systemic chemotherapy. Accordingly, she was treated with sunitinib, which has been regarded as one of the most powerful agents against metastatic RCC , and showed a partial response to this drug. Recently, the favorable clinical activity of sunitinib against non-clear cell carcinomas, including papillary and chromophobe carcinomas, has also been reported [8, 9]; however, this is the first reported case demonstrating a therapeutic response of metastatic CDC to sunitinib. Furthermore, a recent report presented a case of metastatic CDC showing response to sorafenib .
Although the precise molecular mechanism involved in the antitumor activity of multiple tyrosine kinase inhibitors against CDC remains largely unknown, these findings suggest that the efficacy of these agents, for example sunitinib and sorafenib, against metastatic CDC needs to be prospectively evaluated.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Srigley JR, Eble JN: Collecting duct carcinoma of kidney. Semin Diagn Pathol. 1998, 15: 54-67.PubMedGoogle Scholar
- Gollob JA, Upton MP, DeWolf WC, Atkins MB: Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. Urology. 2001, 58: 1058.View ArticlePubMedGoogle Scholar
- Milowsky MI, Rosmarin A, Tickoo SK, Papanicolaou N, Nanus DM: Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer. 2002, 94: 111-116. 10.1002/cncr.10204.View ArticlePubMedGoogle Scholar
- Peyromaure M, Thiounn N, Scotté F, Vieillefond A, Debré B, Oudard S: Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases. J Urol. 2003, 170: 1138-1140. 10.1097/01.ju.0000086616.40603.ad.View ArticlePubMedGoogle Scholar
- Tokuda N, Naito S, Matsuzaki O, Nagashima Y, Ozono S, Igarashi T: Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol. 2006, 176: 40-43. 10.1016/S0022-5347(06)00502-7.View ArticlePubMedGoogle Scholar
- Oudard S, Banu E, Vieillefond A, Fournier L, Medioni J, Banu A, Duclos B, Rolland F, Escudier B, Arekelyan N, Culine S: Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. J Urol. 2007, 177: 1698-1702. 10.1016/j.juro.2007.01.063.View ArticlePubMedGoogle Scholar
- Chao D, Zisman A, Pantuck AJ: Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol. 2002, 167: 71-74. 10.1016/S0022-5347(05)65385-2.View ArticlePubMedGoogle Scholar
- Rini BI, Flaherty K: Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urol Oncol. 2008, 26: 543-549. 10.1016/j.urolonc.2008.03.012.View ArticlePubMedGoogle Scholar
- Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B: Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008, 26: 127-131. 10.1200/JCO.2007.13.3223.View ArticlePubMedGoogle Scholar
- Ansari J, Fatima A, Chaudhri S, Bhatt RI, Wallace M, James ND: Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney. Onkologie. 2009, 32: 44-46. 10.1159/000183736.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.